Please use this identifier to cite or link to this item: https://doi.org/10.1097/QCO.0b013e32833c1d01
DC FieldValue
dc.titleJapanese encephalitis: Update on vaccines and vaccine recommendations
dc.contributor.authorWilder-Smith, A.
dc.contributor.authorHalstead, S.
dc.date.accessioned2016-09-06T08:43:04Z
dc.date.available2016-09-06T08:43:04Z
dc.date.issued2010-10
dc.identifier.citationWilder-Smith, A., Halstead, S. (2010-10). Japanese encephalitis: Update on vaccines and vaccine recommendations. Current Opinion in Infectious Diseases 23 (5) : 426-431. ScholarBank@NUS Repository. https://doi.org/10.1097/QCO.0b013e32833c1d01
dc.identifier.issn09517375
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/126926
dc.description.abstractPurpose of review: Japanese encephalitis is the most common vaccine-preventable viral encephalitis in Asia. In view of the production cessation of the inactivated mouse brain-derived Japanese encephalitis vaccine, it is timely to provide an update on new Japanese encephalitis vaccines and revised vaccine recommendations. Recent findings: A new inactivated, adjuvanted, Vero cell-culture-based Japanese encephalitis vaccine, IC51, was licensed in Europe and the United States in 2009. Administered in a two-dose regimen at 0 and 28 days, it was shown to be well tolerated and produce high seroconversion rates. In addition, Chimerivax Japanese encephalitis, a novel live-attenuated one-dose chimeric vaccine comprising the structural genes of SA 14-14-2 virus and nonstructural genes of yellow fever 17D virus, is in the process of getting licensed in Australia and in south east Asia. Summary: Previous recommendations for Japanese encephalitis vaccination of travelers were predicated on minimizing exposure to a mouse-brain-derived vaccine with a poorly understood and worrisome safety profile, whereas the risk of acquiring Japanese encephalitis itself during travel was assessed to be relatively low. With the availability of a new cell-culture-derived vaccine IC51 with an excellent safety profile, it is appropriate to reconsider benefit-risk considerations for the vaccination of travelers. These considerations are reflected in the March 2010 revised recommendations by the United States Advisory Committee on Immunization Practices. © 2010 Lippincott Williams & Wilkins.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1097/QCO.0b013e32833c1d01
dc.sourceScopus
dc.subjectAdvisory committee on immunization practices
dc.subjectchimeric Japanese encephalitis vaccine
dc.subjectflavivirus
dc.subjectinactivated Japanese encephalitis vaccine IC51
dc.subjectJapanese encephalitis
dc.subjecttravelers
dc.typeReview
dc.contributor.departmentMEDICINE
dc.description.doi10.1097/QCO.0b013e32833c1d01
dc.description.sourcetitleCurrent Opinion in Infectious Diseases
dc.description.volume23
dc.description.issue5
dc.description.page426-431
dc.description.codenCOIDE
dc.identifier.isiut000281653400005
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

30
checked on Jan 15, 2020

WEB OF SCIENCETM
Citations

23
checked on Jan 7, 2020

Page view(s)

37
checked on Jan 17, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.